Suppr超能文献

幽门螺杆菌的治疗。

Treatment of Helicobacter pylori.

机构信息

Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke-University of Magdeburg, Germany.

出版信息

Curr Opin Gastroenterol. 2011 Oct;27(6):565-70. doi: 10.1097/MOG.0b013e32834bb818.

Abstract

PURPOSE OF REVIEW

The article will give an overview on reasons for treatment failure and tries to show new concepts for Helicobacter pylori treatment.

RECENT FINDINGS

Several new treatment options or modifications of already established regimens have been introduced to overcome treatment failure. Antibiotic resistance to H. pylori is the key factor for treatment failure. At the moment, standard triple therapy remains the primary choice in regions with proven low clarithromycin resistance rates. In areas with high clarithromycin resistance, four drug treatment regimens, including quadruple and sequential therapy, have proven the best results as first-line regimens. The options for second-line treatment regimens are manifold. Second-line treatment regimens need to be adapted accurately to local resistance rates.

SUMMARY

Treatment of H. pylori infection is challenged by a dramatic fall in eradication rates all over the world. Newer regimens have been introduced including sequential, quadruple therapies and those regimens provide promising results, but the knowledge about local resistance rates remains the key to an effective therapy.

摘要

目的综述

本文将概述治疗失败的原因,并试图展示幽门螺杆菌治疗的新概念。

最新发现

为了克服治疗失败,已经引入了几种新的治疗选择或已经确立方案的修改。幽门螺杆菌的抗生素耐药性是治疗失败的关键因素。目前,在已经证实克拉霉素耐药率低的地区,标准三联疗法仍然是首选。在克拉霉素耐药率高的地区,包括四联和序贯疗法在内的四种药物治疗方案已被证明是作为一线方案的最佳选择。二线治疗方案的选择多种多样。二线治疗方案需要根据当地耐药率进行准确调整。

总结

全世界的幽门螺杆菌根除率急剧下降,对幽门螺杆菌感染的治疗提出了挑战。已经引入了新的方案,包括序贯疗法、四联疗法,这些方案提供了有希望的结果,但对当地耐药率的了解仍然是有效治疗的关键。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验